Cargando…

Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B

Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in 2019, only 2.2% of CHB patients received treatment. Current international CHB guidelines recommend antiviral treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Young-Suk, Kim, W. Ray, Dieterich, Douglas, Kao, Jia-Horng, Flaherty, John F., Yee, Leland J., Roberts, Lewis R., Razavi, Homie, Kennedy, Patrick T. F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142077/ https://www.ncbi.nlm.nih.gov/pubmed/37112976 http://dx.doi.org/10.3390/v15040997

Ejemplares similares

Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data
por: Lim, Young‐Suk, et al.
Publicado: (2022)

Urgent action to fight hepatitis C in people who inject drugs in Europe
por: Dillon, John F., et al.
Publicado: (2016)

The impact of immigration on hepatitis B burden in the United States: a modelling study
por: Razavi-Shearer, Devin, et al.
Publicado: (2023)

Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden
por: Hajarizadeh, Behzad, et al.
Publicado: (2016)

The Payer License Agreement, or “Netflix model,” for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition
por: Matthews, David W., et al.
Publicado: (2022)

Modelling hepatitis B virus infection and impact of timely birth dose vaccine: A comparison of two simulation models
por: de Villiers, Margaret J., et al.
Publicado: (2020)

Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model — Tashkent, Uzbekistan, December 6, 2019–March 15, 2020
por: Dunn, Rick, et al.
Publicado: (2020)

Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals
por: Gountas, Ilias, et al.
Publicado: (2019)

Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland
por: Müllhaupt, Beat, et al.
Publicado: (2015)

Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States
por: Razavi, Homie, et al.
Publicado: (2013)

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2023)

Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID‐19
por: Blach, Sarah, et al.
Publicado: (2021)

Ten years countdown to hepatitis C elimination in Belgium: a mathematical modeling approach
por: Busschots, Dana, et al.
Publicado: (2022)

Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
por: Müllhaupt, Beat, et al.
Publicado: (2018)

Molecular Epidemiology of Hepatitis B Virus
por: Kao, Jia-Horng
Publicado: (2011)

Cost-effectiveness modelling of birth and infant dose vaccination against hepatitis B virus in Ontario from 2020 to 2050
por: Biondi, Mia J., et al.
Publicado: (2023)

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load
por: Gordon, Stuart C, et al.
Publicado: (2013)

Optimization of hepatitis C virus screening strategies by birth cohort in Italy
por: Kondili, Loreta A., et al.
Publicado: (2020)

Noninvasive Diagnosis of Hepatic Fibrosis in Hemodialysis Patients with Hepatitis C Virus Infection
por: Liu, Chen-Hua, et al.
Publicado: (2022)

HCV elimination among people who inject drugs. Modelling pre- and post–WHO elimination era
por: Gountas, Ilias, et al.
Publicado: (2018)

A micro-elimination approach to addressing hepatitis C in Turkey
por: Idilman, Ramazan, et al.
Publicado: (2020)

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
por: Estes, Chris, et al.
Publicado: (2017)

Elimination of Hepatitis B: Is It a Mission Possible?
por: Tseng, Tai-Chung, et al.
Publicado: (2017)

Hepatitis B e Antigen Status and Hepatitis B DNA Levels in Women of Childbearing Age with Chronic Hepatitis B Infection Screening for Clinical Trials
por: Tran, Tram T., et al.
Publicado: (2015)

A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea
por: Won, Yong Kyun, et al.
Publicado: (2020)

New perspectives of biomarkers for the management of chronic hepatitis B
por: Lin, Chih-Lin, et al.
Publicado: (2016)

Maximizing the cost benefit of physics residency interview
por: Adamson, Justus, et al.
Publicado: (2017)

Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model
por: Binka, Mawuena, et al.
Publicado: (2020)

Nonalcoholic fatty liver disease burden: Australia, 2019–2030
por: Adams, Leon A, et al.
Publicado: (2020)

The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data
por: Palayew, Adam, et al.
Publicado: (2020)

Acute hepatitis C virus infection: clinical update and remaining challenges
por: Liu, Chen-Hua, et al.
Publicado: (2023)

Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030
por: Schaefer, Benedikt, et al.
Publicado: (2018)

All my life to live: travel health benefits and risks for cancer survivors
por: Lim, Jessica Hui Cheah, et al.
Publicado: (2022)

Optimal Strategy and Benefit of Pulsed Therapy Depend On Tumor Heterogeneity and Aggressiveness at Time of Treatment Initiation
por: Mathur, Deepti, et al.
Publicado: (2022)

Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years
por: Buti, Maria, et al.
Publicado: (2015)

HCV infection prevalence in a population recruited at health centers in Jordan
por: Hamoudi, Waseem, et al.
Publicado: (2013)

Disease burden of chronic hepatitis C in Brazil
por: Ferreira, Paulo Roberto Abrão, et al.
Publicado: (2015)

Development of hepatocellular carcinoma in treated and untreated patients with chronic hepatitis B virus infection
por: Lin, Chih-Lin, et al.
Publicado: (2023)

Benefits and Risks of Melatonin in Hepatic and Pancreatic Disorders; A Review of Clinical Evidences
por: Abdi, Saeed, et al.
Publicado: (2021)

Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa
por: Liu, Chen-Hua, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jd46dk7p0an4moaq167ko3e4aa